Wu Ge, Doberstein Stephen K
Five Prime Therapeutics, 1650 Owens St., Suite 200, San Francisco, CA 94158, USA.
Drug Discov Today. 2006 Aug;11(15-16):718-24. doi: 10.1016/j.drudis.2006.06.010.
The concepts and philosophies of HTS can be productively applied to the discovery of new biopharmaceuticals. It is now possible, comprehensively and systematically, to enumerate, clone, produce and screen all secreted proteins, by building upon knowledge accumulated over the past two decades in HTS, genomics and parallel protein expression technologies. Each of the crucial operational components (comprehensive and high-quality cDNA library construction, proper protein-sequence classification, high-throughput protein production, medically relevant assays, state-of-the-art screening and data management) must be optimized to increase the chances of success. In this review, we draw comparisons between small-molecule and protein screening to illuminate common underlying principles as well as differences between the two operations.
高通量筛选（HTS）的概念和理念能够有效地应用于新型生物制药的发现。基于过去二十年来在高通量筛选、基因组学和平行蛋白质表达技术方面积累的知识，现在有可能全面、系统地列举、克隆、生产和筛选所有分泌蛋白。每个关键操作组件（全面且高质量的cDNA文库构建、恰当的蛋白质序列分类、高通量蛋白质生产、医学相关检测、先进的筛选和数据管理）都必须进行优化，以增加成功的机会。在本综述中，我们对小分子筛选和蛋白质筛选进行比较，以阐明两者共同的基本原则以及这两种操作之间的差异。
